Archives
-
Parthenolide, ROS, and Apoptosis in Lymphoid Malignancies
2026-08-12
Jorge and colleagues examined how parthenolide affects diverse lymphoid malignancy models and linked reduced metabolic activity to apoptosis, oxidative stress, glutathione depletion, and mitochondrial dysfunction. The study’s multi-lineage design shows why resazurin-based viability measurements are most informative when paired with mechanistic flow-cytometry and gene-expression endpoints.
-
EDI3 Inhibition in HER2-Therapy-Resistant Breast Cancer
2026-08-11
Keller et al. identify the glycerophosphodiesterase EDI3/GPCPD1 as a metabolic vulnerability enriched in estrogen receptor-negative, HER2-positive breast cancer and associated with resistance to HER2-targeted treatment. Through patient datasets, cell models, pathway perturbation, and an in vivo model, the study shows that genetic or pharmacological EDI3 inhibition reduces cancer-cell viability and tumour growth.
-
Adefovir (GS-0393): HBV Mechanism & Research
2026-08-11
Adefovir (GS-0393) is a nucleotide analog antiviral that forms adefovir diphosphate and inhibits HBV DNA polymerase. Its research value also includes use as an OAT1 probe, while renal handling and bone-safety limits require careful translational interpretation.
-
UTP Solution (100 mM) for RNA Assay Design
2026-08-10
UTP Solution (100 mM) is more than a nucleotide stock: it is a controllable input for RNA assay design. This article connects UTP chemistry with the TRIM66 study of olfactory receptor choice while defining what the evidence does—and does not—support experimentally.
-
Propranolol Workflows for Translational Research
2026-08-09
Propranolol enables controlled β1 and β2 receptor perturbation across cardiovascular, neurobehavioral, metabolic, and regenerative research. This workflow-focused guide shows how to pair the compound with multiplex mRNA detection, immunohistochemistry, and EdU labeling while avoiding vehicle, timing, and interpretation errors.
-
Aurora A as a Translational Vulnerability
2026-08-08
Aurora A biology is moving from a mitotic concept to a testable translational strategy. This article examines how MLN8237 (Alisertib) can help researchers connect AURKA overexpression, MYCN-associated tumor biology, apoptosis induction, and preclinical response—using retinoblastoma as a focused example while preserving the discipline required for target validation.
-
Remdesivir: Polymerase-Aware Antiviral Research
2026-08-07
Remdesivir and GS-5734 provide a powerful framework for studying RNA-virus polymerase inhibition. This article connects phenotypic antiviral assays with new structural insights into polymerase organization, clarifying what experimental results can—and cannot—support across coronavirus, Ebola, and Nipah virus research.
-
Z-VEID-FMK: Strategic Caspase-6 Inhibition for Translational
2026-08-07
Explore how Z-VEID-FMK, a high-purity, irreversible caspase-6 inhibitor, empowers research into apoptosis and neurodegeneration. This article offers mechanistic insights, translational strategies, and protocol guidance—anchored in recent host–pathogen studies and advanced workflow expertise.
-
3-Deazaneplanocin (DZNep): Epigenetic Modulator for Oncology
2026-08-06
3-Deazaneplanocin (DZNep) empowers researchers with precision epigenetic modulation, enabling apoptosis induction in AML and targeting cancer stem cells in hepatocellular carcinoma. Discover robust protocols, troubleshooting insights, and strategic integration for advanced oncology and metabolic disease models.
-
Pronase E Protease Mixture: Precision in Protein Sample Prep
2026-08-06
Pronase E sets the benchmark for unbiased, high-efficiency protein digestion in proteomics and molecular biology. Its robust activity streamlines workflows targeting challenging pathways such as ferroptosis, enabling consistent, reproducible results for advanced mechanistic studies.
-
Phosphatase Inhibitor Cocktail: Precision in Phosphorylation
2026-08-05
The Phosphatase Inhibitor Cocktail (2 Tubes, 100X) by APExBIO redefines protein phosphorylation preservation, combining robust inhibition of both serine/threonine and tyrosine phosphatases in a uniquely flexible protocol. Its dual-tube system excels in advanced workflows like immunoblotting, kinase activity assays, and mass spectrometry, enabling reproducibility and sensitivity essential for translational research.
-
Pseudo-UTP: Pseudo-modified Uridine Triphosphate for mRNA Sy
2026-08-05
Pseudo-UTP, a pseudo-modified uridine triphosphate, enables enhanced mRNA synthesis with improved RNA stability and reduced immunogenicity. Incorporation of Pseudo-UTP is a validated strategy for advancing mRNA vaccine development and gene therapy applications.
-
Topotecan (SKF104864): Optimizing Cancer Research Workflows
2026-08-04
Topotecan (SKU B4982) from APExBIO enables precise, reproducible apoptosis and cell cycle studies in glioma and pediatric tumor models, thanks to its robust topoisomerase I inhibition and validated high-purity formulation. This guide delivers actionable workflows, protocol enhancements, and troubleshooting strategies to maximize experimental success and translational impact.
-
Synergistic Lipid Nanoparticles Enhance mRNA Shingles Vaccin
2026-08-04
A recent study introduces a synergistic lipid nanoparticle (Syn-LNP) platform encapsulating mRNA encoding VZV glycoprotein E, achieving potent and durable immune responses against shingles in animal models. This work demonstrates how optimized delivery and mRNA design can address supply chain and efficacy limitations of current vaccines.
-
Ridaforolimus: Applied mTOR Inhibition in Senescence & Cance
2026-08-03
Ridaforolimus (Deforolimus, MK-8669) empowers precision mTOR pathway inhibition in cancer and senescence research, with low-nanomolar potency and robust anti-proliferative action. This guide distills practical protocols, AI-driven discovery insights, and advanced troubleshooting for maximum reproducibility in translational studies.